US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.93

-0.0400-1.35%

Pre-market: 2.88-0.0549-1.87%04:39 EDT

Volume:175.07K

Turnover:512.33K

Market Cap:44.30M

PE:-0.92

High:2.98

Open:2.98

Low:2.86

Close:2.97

52wk High:10.00

52wk Low:2.13

Shares:15.12M

Float Shares:9.60M

Volume Ratio:0.73

T/O Rate:1.82%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1959

EPS(LYR):-2.9824

ROE:-107.62%

ROA:-60.80%

PB:1.93

PE(LYR):-0.98

Loading ...

Overview Company News Filings

CervoMed Q2 Net Loss Lower than Estimates as Costs Drop

CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate

Benzinga Earnings

Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview

CervoMed’s neflamapimod gains UK Innovation Passport

CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)

THOMSON REUTERS

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

CervoMed advances neflamapimod strategy with new DLB data

Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial

Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)

THOMSON REUTERS

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

CervoMed completes enrollment in neflamapimod study

Cervomed Completes Enrollment in Phase 2a Neflamapimod Trial for Nonfluent PPA

Cervomed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

THOMSON REUTERS

Cervomed - Interim Biomarker Data from Nfvppa Trial Expected Early Q4 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/CRVO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.93,"timestamp":1790884800000,"preClose":2.97,"halted":0,"volume":175071,"hourTrading":{"tag":"盘前","latestPrice":2.8751,"preClose":2.93,"latestTime":"04:39 EDT","volume":462,"amount":1341.5885406,"timestamp":1790930399108,"change":-0.0549,"changeRate":-0.018737,"amplitude":0.018737},"delay":0,"changeRate":-0.01346801346801348,"floatShares":9604400,"shares":15119100,"eps":-3.195903,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"10-02 04:41:42 EDT","open":2.98,"high":2.98,"low":2.86,"amount":512330.6105502,"amplitude":0.040404,"askPrice":3.19,"askSize":144,"bidPrice":2.85,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":2.93,"preHourTrading":{"tag":"盘前","latestPrice":2.8751,"preClose":2.93,"latestTime":"04:39 EDT","volume":462,"amount":1341.5885406,"timestamp":1790930399108,"change":-0.0549,"changeRate":-0.018737,"amplitude":0.018737},"postHourTrading":{"tag":"盘后","latestPrice":2.9299,"preClose":2.93,"latestTime":"19:53 EDT","volume":3288,"amount":9583.9653,"timestamp":1790898798187,"change":-0.0001,"changeRate":-0.000034,"amplitude":0.010239},"volumeRatio":0.7297714360576762},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":9604400,"roa":"-60.80%","roe":"-107.62%","lyrEps":-2.982424,"volumeRatio":0.7297714360576762,"shares":15119100,"dividePrice":0,"high":2.98,"amplitude":0.040404,"preClose":2.97,"low":2.86,"week52Low":2.13,"pbRate":"1.93","psRate":"133.71","week52High":10,"institutionHeld":0,"latestPrice":2.93,"committee":-0.655172,"eps":-3.195903,"divideRate":0,"volume":175071,"delay":0,"ttmEps":-3.195903,"open":2.98,"prevYearClose":7.9,"prevWeekClose":2.54,"prevMonthClose":2.97,"prevQuarterClose":2.97,"fiveDayClose":2.52,"twentyDayClose":2.64,"sixtyDayClose":3.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"CRVO","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-05-15","symbol":"CRVO","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2026-03-13","symbol":"CRVO","fiscalQuarterEnding":"2025/12","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773374400000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2025-11-07","symbol":"CRVO","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":6,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2026-09-30","current":-0.916799,"percent":0.83724,"low":-119.682483,"twenty":-31.843087,"median":-3.94807,"eighty":-1.506059,"high":-0.69356,"avg":-16.235065,"sd":23.03376,"marketCap":43542996},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-31","current":-2.909391,"twenty":-38.804612,"median":-7.450846,"eighty":-3.374238,"marketCap":65786832},{"date":"2025-11-07","current":-2.983046,"twenty":-38.663931,"median":-7.254628,"eighty":-3.361323,"marketCap":67452321},{"date":"2025-11-14","current":-2.621936,"twenty":-38.6419,"median":-7.20399,"eighty":-3.333221,"marketCap":67082212},{"date":"2025-11-21","current":-3.258434,"twenty":-38.625998,"median":-7.137979,"eighty":-3.315314,"marketCap":83366998},{"date":"2025-11-28","current":-3.594765,"twenty":-38.625995,"median":-6.963795,"eighty":-3.314496,"marketCap":91972026},{"date":"2025-12-05","current":-3.276516,"twenty":-38.456214,"median":-6.708179,"eighty":-3.314142,"marketCap":83829634},{"date":"2025-12-12","current":-2.961884,"twenty":-38.413768,"median":-6.632186,"eighty":-3.290836,"marketCap":75779768},{"date":"2025-12-19","current":-2.857006,"twenty":-38.350099,"median":-6.354912,"eighty":-3.258434,"marketCap":73096480},{"date":"2025-12-26","current":-3.066761,"twenty":-38.300453,"median":-6.221623,"eighty":-3.198527,"marketCap":78463057},{"date":"2026-01-02","current":-2.857006,"twenty":-38.248873,"median":-6.028218,"eighty":-3.184173,"marketCap":73096480},{"date":"2026-01-09","current":-2.846157,"twenty":-38.210281,"median":-5.866832,"eighty":-3.139814,"marketCap":72818898},{"date":"2026-01-16","current":-2.560456,"twenty":-38.170115,"median":-5.764162,"eighty":-3.103963,"marketCap":65509250},{"date":"2026-01-23","current":-2.379633,"twenty":-38.109126,"median":-5.691463,"eighty":-3.066761,"marketCap":60882891},{"date":"2026-01-30","current":-1.869712,"twenty":-37.999948,"median":-5.513005,"eighty":-3.019747,"marketCap":47836557},{"date":"2026-02-06","current":-1.663573,"twenty":-37.887707,"median":-5.323443,"eighty":-2.9876,"marketCap":42562507},{"date":"2026-02-13","current":-1.638258,"twenty":-37.814908,"median":-5.250814,"eighty":-2.957395,"marketCap":41914817},{"date":"2026-02-20","current":-1.89141,"twenty":-37.791053,"median":-5.231258,"eighty":-2.930623,"marketCap":48391720},{"date":"2026-02-27","current":-1.591244,"twenty":-37.763222,"median":-5.212816,"eighty":-2.89957,"marketCap":40711963},{"date":"2026-03-06","current":-1.450202,"twenty":-37.64792,"median":-5.171192,"eighty":-2.886661,"marketCap":37103403},{"date":"2026-03-13","current":-1.565929,"twenty":-37.601604,"median":-5.067362,"eighty":-2.872563,"marketCap":40064273},{"date":"2026-03-20","current":-1.452342,"twenty":-37.462974,"median":-5.060142,"eighty":-2.848327,"marketCap":39164381},{"date":"2026-03-27","current":-1.345905,"twenty":-37.39506,"median":-5.023312,"eighty":-2.81779,"marketCap":36294178},{"date":"2026-04-02","current":-1.373373,"twenty":-37.39506,"median":-5.008257,"eighty":-2.777444,"marketCap":37034876},{"date":"2026-04-10","current":-1.383673,"twenty":-37.352614,"median":-4.96552,"eighty":-2.744896,"marketCap":37312637},{"date":"2026-04-17","current":-1.369939,"twenty":-37.352614,"median":-4.878764,"eighty":-2.677991,"marketCap":36942288},{"date":"2026-04-24","current":-1.321871,"twenty":-37.289369,"median":-4.834638,"eighty":-2.621936,"marketCap":35646068},{"date":"2026-05-01","current":-1.266936,"twenty":-37.075389,"median":-4.791246,"eighty":-2.520675,"marketCap":34164673},{"date":"2026-05-08","current":-1.304704,"twenty":-37.013045,"median":-4.759848,"eighty":-2.379633,"marketCap":35183132},{"date":"2026-05-15","current":-1.29097,"twenty":-36.657918,"median":-4.726862,"eighty":-1.989055,"marketCap":34812783},{"date":"2026-05-22","current":-0.952489,"twenty":-36.618159,"median":-4.701084,"eighty":-1.869712,"marketCap":28609441},{"date":"2026-05-29","current":-0.967902,"twenty":-36.524547,"median":-4.684546,"eighty":-1.778577,"marketCap":29072377},{"date":"2026-06-05","current":-0.961737,"twenty":-36.333397,"median":-4.581202,"eighty":-1.73518,"marketCap":28887203},{"date":"2026-06-12","current":-0.752128,"twenty":-36.234746,"median":-4.538149,"eighty":-1.677316,"marketCap":22591274},{"date":"2026-06-18","current":-1.174429,"twenty":-36.1867,"median":-4.529194,"eighty":-1.658046,"marketCap":35275719},{"date":"2026-06-26","current":-1.508594,"twenty":-36.138654,"median":-4.51746,"eighty":-1.640428,"marketCap":45312880},{"date":"2026-07-02","current":-1.661705,"twenty":-35.994244,"median":-4.482916,"eighty":-1.622122,"marketCap":49911799},{"date":"2026-07-10","current":-1.684222,"twenty":-35.726787,"median":-4.41968,"eighty":-1.609687,"marketCap":50588111},{"date":"2026-07-17","current":-1.414026,"twenty":-35.527938,"median":-4.351268,"eighty":-1.601689,"marketCap":42472371},{"date":"2026-07-24","current":-1.202372,"twenty":-35.095242,"median":-4.262561,"eighty":-1.59587,"marketCap":36115042},{"date":"2026-07-31","current":-1.134823,"twenty":-34.627571,"median":-4.241728,"eighty":-1.588961,"marketCap":34086107},{"date":"2026-08-07","current":-1.242902,"twenty":-34.501534,"median":-4.181454,"eighty":-1.572341,"marketCap":37332403},{"date":"2026-08-14","current":-1.459615,"twenty":-34.113333,"median":-4.141074,"eighty":-1.56639,"marketCap":44298951},{"date":"2026-08-21","current":-1.275295,"twenty":-34.018436,"median":-4.117333,"eighty":-1.548892,"marketCap":38704885},{"date":"2026-08-28","current":-1.315148,"twenty":-33.795627,"median":-4.092569,"eighty":-1.540602,"marketCap":39914413},{"date":"2026-09-04","current":-1.265332,"twenty":-33.11242,"median":-4.089924,"eighty":-1.53948,"marketCap":38402503},{"date":"2026-09-11","current":-1.235442,"twenty":-32.960319,"median":-4.048287,"eighty":-1.533693,"marketCap":37495358},{"date":"2026-09-18","current":-1.270314,"twenty":-32.304293,"median":-4.022407,"eighty":-1.526784,"marketCap":38553694},{"date":"2026-09-25","current":-1.255369,"twenty":-32.045859,"median":-3.964385,"eighty":-1.512967,"marketCap":38100121},{"date":"2026-09-30","current":-1.434707,"twenty":-31.843087,"median":-3.94807,"eighty":-1.506059,"marketCap":43542996}],"updateTime":1790896282076},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658443933","title":"CervoMed Q2 Net Loss Lower than Estimates as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2658443933","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658443933?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:38","pubTimestamp":1786361915,"startTime":"0","endTime":"0","summary":"CervoMed Q2 net loss lower than estimates as costs dropOverviewUS biotech developer's Q2 net loss was lower than analyst expectationsCompany completed $20.5 mln equity financings, extending cash runwa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRVO","BK4585","BK4505","PTH","BK4139","LU2324357040.USD","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933970","title":"CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933970","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933970?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:33","pubTimestamp":1786361613,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61070579/cervomed-q2-eps-0-64-misses-0-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933484","title":"Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933484?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"partnership to advance its neflamapimod program into a Phase 3 clinical. -- CervoMed received a notice of allowance from the U.S. Patent and. Trademark Office in June 2026 for a new patent covering the use of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345774391.USD","BK4097","DLB","LU0348723411.USD","LU0240878834.USD","AD","BK4110","LU0345774631.USD","BK4139","LU0205193047.USD","LU0240877869.USD","BK4132","LU0205194284.USD","AAIC","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621505","title":"CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621505","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621505?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:01","pubTimestamp":1786140102,"startTime":"0","endTime":"0","summary":"CervoMed Inc reports results for the quarter ended June 30 - Earnings SummaryCervoMed IncCRVO.OQreported a quarterly adjusted loss of 64 cents per share for the quarter ended June 30, higher than the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626905","title":"Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626905","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626905?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:28","pubTimestamp":1786134486,"startTime":"0","endTime":"0","summary":"Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to noneCervomed posted a net loss of $6.57 million in Q2, widening 5% from the prior-year quarter.Operating loss was $6.68 million, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1JMhz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542295","title":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542295","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542295?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  05, 2026  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339214/0/en/CervoMed-to-Participate-in-Fireside-Chat-to-Highlight-Recent-Progress-in-the-Neflamapimod-Clinical-Development-Program-at-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRGS","BK4097","CRVO","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656551361","title":"CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656551361","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656551361?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:23","pubTimestamp":1785849786,"startTime":"0","endTime":"0","summary":"CervoMed Inc <CRVO.OQ> expected to post a loss of87cents a share - Earnings PreviewCervoMed IncCRVO.OQCRVO.Ois expected to  show a fall in quarterly revenue when it reports  results on August 6 (estim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555079","title":"CervoMed’s neflamapimod gains UK Innovation Passport","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555079?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:19","pubTimestamp":1785845960,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has provided an announcement. On August 4, 2026, CervoMed announced that neflamapimod, its oral small-molecule drug targeting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553429","title":"CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553429?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:52","pubTimestamp":1785844374,"startTime":"0","endTime":"0","summary":"CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementiaCervoMed’s neflamapimod received an Innovation Passport under the UK Innovative Licensing and Access Pathway for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLWFK2r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656115539","title":"CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656115539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656115539?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA7XJGMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118452","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651118452?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:50","pubTimestamp":1784112600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 15, 2026 06:50 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651582584","title":"CervoMed advances neflamapimod strategy with new DLB data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651582584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651582584?lang=en_us&edition=fundamental","pubTime":"2026-07-15 15:44","pubTimestamp":1784101487,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has issued an update. On July 14, 2026, CervoMed reported new clinical, plasma biomarker and imaging data for neflamapimod in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-strategy-with-new-dlb-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-advances-neflamapimod-strategy-with-new-dlb-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139","DLB","BK4097","LU0240877869.USD","LU0205194284.USD","LU0240878834.USD","LU0345774391.USD","LU0345774631.USD","LU0348723411.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651108822","title":"Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651108822","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651108822?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:35","pubTimestamp":1784028920,"startTime":"0","endTime":"0","summary":"CervoMed reports new Phase 2b data supporting neflamapimod 50 mg TID dose for planned DLB Phase 3 trialCervoMed presented new AAIC 2026 analyses supporting 50 mg three-times-daily neflamapimod as the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL9cVVpd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170037","title":"Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651170037?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:30","pubTimestamp":1784028601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA3WFHYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651136371","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651136371","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651136371?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:25","pubTimestamp":1783938300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 06:25 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929730","title":"Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929730?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:59","pubTimestamp":1783598340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 07:59 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929961","title":"CervoMed completes enrollment in neflamapimod study","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929961?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:40","pubTimestamp":1783597246,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-completes-enrollment-in-neflamapimod-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-completes-enrollment-in-neflamapimod-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650293179","title":"Cervomed Completes Enrollment in Phase 2a Neflamapimod Trial for Nonfluent PPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2650293179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650293179?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:34","pubTimestamp":1783596848,"startTime":"0","endTime":"0","summary":"CervoMed completes enrollment in Phase 2a neflamapimod trial for nonfluent PPACervoMed completed enrollment in a Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, a form","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL53chWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929812","title":"Cervomed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929812?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:30","pubTimestamp":1783596601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA1ZZBXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929804","title":"Cervomed - Interim Biomarker Data from Nfvppa Trial Expected Early Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929804?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:30","pubTimestamp":1783596601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA1ZZBXK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":106,"code":"91000000","status":"200"}]}}